Free Trial
NYSE:FNA

Paragon 28 (FNA) Stock Price, News & Analysis

Paragon 28 logo
$13.10 +0.02 (+0.11%)
Closing price 04/17/2025
Extended Trading
$13.10 0.00 (0.00%)
As of 04/17/2025 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Paragon 28 Stock (NYSE:FNA)

Key Stats

Today's Range
$13.07
$13.11
50-Day Range
$12.98
$13.11
52-Week Range
$4.65
$13.13
Volume
19.38 million shs
Average Volume
1.10 million shs
Market Capitalization
$1.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.20
Consensus Rating
Hold

Company Overview

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Paragon 28 Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

FNA MarketRank™: 

Paragon 28 scored higher than 28% of companies evaluated by MarketBeat, and ranked 817th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Paragon 28 has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Paragon 28 has received no research coverage in the past 90 days.

  • Read more about Paragon 28's stock forecast and price target.
  • Earnings Growth

    Earnings for Paragon 28 are expected to grow in the coming year, from ($0.64) to ($0.47) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Paragon 28 is -17.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Paragon 28 is -17.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Paragon 28 has a P/B Ratio of 6.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Paragon 28's valuation and earnings.
  • Percentage of Shares Shorted

    2.22% of the float of Paragon 28 has been sold short.
  • Short Interest Ratio / Days to Cover

    Paragon 28 has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Paragon 28 has recently decreased by 17.05%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Paragon 28 does not currently pay a dividend.

  • Dividend Growth

    Paragon 28 does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.22% of the float of Paragon 28 has been sold short.
  • Short Interest Ratio / Days to Cover

    Paragon 28 has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Paragon 28 has recently decreased by 17.05%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Paragon 28 insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,810,399.00 in company stock.

    • Percentage Held by Insiders

      15.32% of the stock of Paragon 28 is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      63.57% of the stock of Paragon 28 is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Paragon 28's insider trading history.
    Receive FNA Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Paragon 28 and its competitors with MarketBeat's FREE daily newsletter.

    FNA Stock News Headlines

    Here’s How to Claim Your Stake in Elon’s Private Company, xAI
    Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
    See More Headlines

    FNA Stock Analysis - Frequently Asked Questions

    Paragon 28's stock was trading at $10.33 at the beginning of the year. Since then, FNA shares have increased by 26.9% and is now trading at $13.1050.
    View the best growth stocks for 2025 here
    .

    Paragon 28, Inc. (NYSE:FNA) posted its quarterly earnings data on Thursday, March, 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.01. The firm earned $71.75 million during the quarter, compared to analysts' expectations of $70.81 million. Paragon 28 had a negative net margin of 25.31% and a negative trailing twelve-month return on equity of 37.90%.

    Paragon 28 (FNA) raised $125 million in an initial public offering on Friday, October 15th 2021. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. BofA Securities and Piper Sandler served as the underwriters for the IPO and Canaccord Genuity, JMP Securities and Needham & Company were co-managers.

    Top institutional investors of Paragon 28 include Trium Capital LLP (3.33%), CIBRA Capital Ltd (1.11%), HighMark Wealth Management LLC (0.48%) and Deltec Asset Management LLC (0.18%). Insiders that own company stock include Mvm Partners Llp, B Ag Bird, Mvm Partners, Llc, Albert Dacosta, Frank S Bono, Matthew Jarboe, Lee Rosenthal, Thomas P Schnettler and Kristina Wright.
    View institutional ownership trends
    .

    Shares of FNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Paragon 28 investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

    Company Calendar

    Last Earnings
    3/06/2025
    Today
    5/05/2025
    Next Earnings (Estimated)
    5/14/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NYSE
    Sector
    Medical
    Industry
    Surgical & medical instruments
    Sub-Industry
    Medical Equipment
    Current Symbol
    NYSE:FNA
    Fax
    N/A
    Employees
    343,000
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $14.20
    High Stock Price Target
    $20.00
    Low Stock Price Target
    $12.00
    Potential Upside/Downside
    +8.4%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.33
    Research Coverage
    6 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $-57,530,000.00
    Pretax Margin
    -26.58%

    Debt

    Sales & Book Value

    Annual Sales
    $256.18 million
    Price / Cash Flow
    N/A
    Book Value
    $2.05 per share
    Price / Book
    6.39

    Miscellaneous

    Free Float
    70,894,000
    Market Cap
    $1.10 billion
    Optionable
    Optionable
    Beta
    1.47
    The 10 Best AI Stocks to Own in 2025 Cover

    Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

    Get This Free Report

    This page (NYSE:FNA) was last updated on 5/5/2025 by MarketBeat.com Staff
    From Our Partners